Different regulatory effects of pentoxifylline on human T cell activation pathways
Different regulatory effects of pentoxifylline on human T cell activation pathways
复制标题
DOI：
10.1023/a:1027362629161
复制
发表时间：
1997-05-01
影响因子：
9.1
通讯作者：
Morimoto, C
中科院分区：
文献类型：
--
作者：
Dong, RP;Umezawa, Y;Morimoto, C
分别用抗CD3单抗、抗CD3与PMA、抗CD3与抗CD26、抗CDS与抗CD28单抗联用，观察己酮可可碱(PTX)对单独抗CD3、抗CD3与PMA、抗CD3与抗CD28单抗刺激T细胞增殖和细胞因子产生的影响。在3.5×10(-5)M浓度下，PTX显著抑制T细胞的增殖和肿瘤坏死因子-α、白介素2和白介素4的产生。此外，这种作用对抗CD3抗体与PMA或抗CD3抗体与抗CD26抗体的刺激具有选择性，但对抗CDS抗体与抗CD28抗体的作用不具有选择性。这些结果提示，PTX对T细胞活化的抑制作用涉及CD3和CD26，而不是CD28信号通路。
Pentoxifylline (PTX), a methylxanthine derivative, was examined for its effects on T cell proliferation and cytokine production stimulated by cross-linking anti-CD3 alone, anti-CD3 with PMA, anti-CD3 with anti-CD26, or anti-CDS with anti-CD28 mAb, respectively. PTX at a 3.5 x 10(-5) M concentration significantly inhibited T cell proliferation and the production of tumor necrosis factor-alpha, interleukin-2, and interleukin-4. Moreover, this effect was selective for stimulation by cross-linking anti-CD3 with PMA, or anti-CD3 with anti-CD26, but not by cross-linking anti-CDS with anti-CD28. These results suggest that the inhibitory effect of PTX on T cell activation involves the CD3 and CD26, but not the CD28 signal pathway.